Why the Incannex (ASX:IHL) share price is climbing 5% this morning

The Incannex Healthcare Ltd (ASX: IHL) share price is climbing 5% on the back of a positive update regarding its therapy, IHL-675A.

| More on:
A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Incannex Healthcare Ltd (ASX: IHL) share price is climbing on the back of a positive update regarding its therapy, IHL-675A.

At the time of writing, the healthcare company's shares are up 5%, trading at 21 cents.

What did Incannex announce?

The Incannex share price is on the move today as investors appear pleased with the company's progress.

In its release, Incannex advised that it has been granted a pre-IND meeting with the United States Food and Drug Administration (FDA). The meeting follows the company's submitted information package, which contained details of IHL-675A and its medical benefits.

IHL-675A is a novel therapy that comprises hydroxychloroquine (HCQ) and cannabidiol (CBD) for the potential treatment of Acute Respiratory Distress Syndrome (ARDS) and sepsis-associated Adult Respiratory Distress Syndrome (SAARDS).

Incannex stated that the FDA is scheduled to provide feedback on the development proposal for IHL-675A by 21 April 2021. Once received, the company will seek to finalise clinical development plans with suggestions from the FDA.

The purpose of the pre-IND meeting is to explore the fastest pathway for IHL-675A to be given its registration stamp.

ARDS is a type of respiratory failure which collects fluid into the air sacs of the lungs. This is often caused by infection or trauma and can result in death if not treated. It is estimated that 10% to 15% of patients admitted to intensive care suffering from ARDS.

SAARDS, caused by infection, is associated with lung, urinary tract, stomach, skin infections and COVID-19 viral infections.

Management commentary

Incannex CEO and managing director Joel Latham welcomed the positive outcome, saying:

The United States is the largest pharmaceutical market in the world, so being granted a Pre-IND meeting review with FDA represents an important milestone for our company and a strong foundation for the clinical development of IHL-675A.

Our preclinical studies have demonstrated that IHL-675A has the potential to be a platform drug applicable to the treatment of multiple indications. We anticipate that the work completed on the FDA information package for IHL-675A for ARDS and SAARDS will assist us with hastening submissions to FDA for the other indications being pursued.

About the Incannex share price

The Incannex share price has gained more than 500% in the past 12 months and is up almost 30% year-to-date. The company's shares reached a multi-year high of 29.5 cents in the last month.

Incannex commands a market capitalisation of around $211 million, with roughly 1 billion shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Market News

5 fantastic ASX ETFs to buy with $5,000

These funds could be worth a closer look. Here's what you need to know about them.

Read more »

Happy young woman saving money in a piggy bank.
Share Gainers

3 ASX shares that would already have more than doubled your money in 2025

An investment in any of these ASX shares on 2 January would have more than doubled your money by now.

Read more »

woman talking on the phone and giving financial advice whilst analysing the stock market on the computer with a pen
Share Market News

How did your first quarter performance compare to Australian fund managers?

How did you measure up?

Read more »

A man working in the stock exchange.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A panel of four judges hold up cards all showing the perfect score of ten out of ten
Broker Notes

10 best shares to buy today in Australia

Analysts think these shares are among the best to buy now.

Read more »

A boy is excited because he won the computer game.
Share Market News

Telix: A masterclass in what this game is all about

Today's market darling reminds us why we love to invest. But is it too late?

Read more »

A happy youngster holds a giant bag of carrots at a supermarket fruit and vegie section, indicating savings made by buying in bulk.
Opinions

Are these the best US stocks to consider buying right now?

I think these stocks would do well in any portfolio today.

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a great end to the week's trading today...

Read more »